Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Premedication in Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Normotensive~* Hypertension with stage 1 or 2~* Scheduled for myomectomy or hysterectomy operation~* Aged 40-60~* ASA I or II~* BMI is under 30 kg/m2~Exclusion Criteria:~* Untreated hypertension~* Users of ACE inhibitors as antihypertensive therapy~* History of severe cardiovascular disease, renal disease, diabetes mellitus, cerebrovascular disease~* An allergy to study drugs~* Difficult airway~* If the time more than fifteen minutes between the start of surgery and the induction~* If necessary blood transfusion was required

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group HD (Type: ACTIVE_COMPARATOR): Dexmedetomidine was administered 0.5 µg.kg-1 in hypertensive patient
- Group ND (Type: SHAM_COMPARATOR): Dexmedetomidine was administered 0.5 µg.kg-1 in normotensive patient
- Group HM (Type: ACTIVE_COMPARATOR): Midazolam was administered 0.025 mg. kg-1 in hypertensive patient.
- Group NM (Type: SHAM_COMPARATOR): Midazolam was administered 0.025 mg. kg-1 in normotensive patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).